Analysis of the low levels of catecholamines and metabolites in tissue and biological uids has necessitated the use of highly sensitive analytical techniques. Earlier procedures utilizing radioenzymatic and immunological assays, gas chromatography or uorimetry have generally been superseded by highly sensitive and selective chromatographic methods utilizing electrochemical or uorimetric detection. The development of high-performance liquid chromatography (HPLC) methods for the measurement of plasma metadrenalines and the combination of HPLC with tandem mass spectrometry provides additional procedures with minimum interference from drugs and drug metabolites. This review summarizes the methodology currently available for the measurement of catecholamines and metabolites in plasma and urine, the in uence of sample collection protocols and the clinical application of the methods for the biochemical detection of catecholamine-secreting tumours.
Introduction
The catecholamines of clinical interest^noradrenaline, adrenaline and dopamine^are important neurotransmitters in the sympathetic nervous system which exert cardiovascular and metabolic e¡ects by stimulating adrenergic receptors in a wide variety of cells. The excessive production and release into the circulation of catecholamines by a neoplasm of chroma¤n tissue such as phaeochromocytoma characteristically produces paroxysmal or persistent hypertension. Although a rare cause of hypertension, early diagnosis is imperative to avoid the complications associated with the excessive tumoral release of catecholamines. Fundamental to the detection and diagnosis of chroma¤n cell tumours is the measurement of plasma or urinary catecholamines and their metabolites.
Historically, the adrenal medulla was ¢rst demonstrated to be the source of a potent pressor substance by Oliver and Schafer in 1895; 1 this substance was subsequently isolated and identi¢ed as a catecholamine in 1897. 2 It was ¢nally characterized by Takamine 3 and Aldrich 4 independently in 1901. Takamine applied the term`adrenaline' while Aldrich puri¢ed and named the active compound epinephrine'. It was not until 1946 that the exact chemical nature of the sympathomimetic substance was ¢nally elucidated 5 and the fact that noradrenaline was the main sympathetic transmitter was aptly demonstrated by Peart in 1949. 6 Chemically, catecholamines are monoamines linked to a benzene ring with two vicinal hydroxyl groups (catechol). The ring structure not only makes the compounds naturally £uorescent but also sensitive to light and easily oxidized. Early analytical procedures for the estimation of catecholamines in plasma and urine exploited their £uorescent properties by using methods based on either trihydroxyindole -or ethylenediamine-derived £uorescent derivatives. 7^9 The principal degradation pathway of the catecholamines was unknown until 1956 when Armstrong et al. demonstrated the presence of organic acids possessing a 4-hydroxy-3-methoxy group in human urine 10 and further illustrated the importance of methylation in catecholamine metabolism by isolating the metabolite 4-hydroxy-3-methoxymandelic acid (HMMA). 11 Other reports followed showing the existence of methoxylated amine metabolites^normetadrenaline and metadrenaline^together with the end-product of dopamine metabolism, homovanillic acid (HVA). 12, 13 Before long, spectrophotometric procedures for the analysis of urinary levels of HMMA Review Article and total metadrenalines were devised and were the most frequently applied biochemical tests for the detection of neural crest tumours such as phaeochromocytoma. 14, 15 However, the introduction of gas chromatography (GC) and high-performance liquid chromatography (HPLC) techniques allowed the quanti¢cation of these catecholamine metabolites with a greater degree of sensitivity and speci¢city, eliminating many problems associated with previous spectrophotometric assays.
Biochemistry of catecholamines

Synthesis
The three catecholamines dopamine, adrenaline and noradrenaline are all derivatives of dihydroxyphenylalanine (DOPA), a catecholic amino acid. Dopamine and noradrenaline are primary amines whereas adrenaline is a secondary amine. The initial step in the biosynthetic pathway (see Fig. 1 ) involves hydroxylation of the amino acid L-tyrosine to DOPA, a ratelimiting step before decarboxylation of DOPA to dopamine, 16 the principal central neurotransmitter in parts of the central nervous system associated with motor control. The introduction of a b-hydroxyl group by dopamine b-hydroxylase forms noradrenaline, 17 while the addition of a methyl group onto the amino group of noradrenaline forms adrenaline, signi¢cantly altering the pharmacology of the catecholamine. Noradrenaline is the ¢nal product in the central and peripheral adrenergic systems, whereas in the adrenal medulla it is further metabolized to adrenaline.
Storage and release of catecholamines
The main sites of catecholamine production are the brain, the adrenal medulla and sympathetic neurons. Following their synthesis, catecholamines are stored chemically unchanged within the chroma¤n granules of the adrenal medulla and in post-ganglionic neurons in membrane-bound storage vesicles. Within the storage vesicle, catecholamines are complexed to non-di¡usible proteins (chromogranins) which serve to inactivate and prevent enzymatic degradation until exocytotic release of the contents of the vesicle. Although chroma¤n cell tumours may secrete a variety of biologically active neuropeptides, 18 the dominant secretory products are the catecholamines. With a plasma half-life of approximately 1-2 min, the catecholamines exert their diverse physiological e¡ects by binding to a and b plasma membrane receptors that are collectively known as adrenergic receptors, classi¢ed according to their a¤nity for various agonists or antagonists. Dopamine also stimulates a-and b-adrenergic receptors as well as dopamine receptors, resulting in increased systolic blood pressure and cardiac output.
Inactivation and metabolism of catecholamines
Only a small fraction of the catecholamine released from the storage vesicle binds to post-ganglionic receptors, the majority being e¤ciently removed by neuronal and extraneuronal uptake such that only a small fraction escapes into the circulation. 19 Tricyclic antidepressants and cocaine e¡ectively block the neuronal reuptake process. The principal pathways for the metabolism of the catecholamines entering the circulation involves two enzymes, monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT), leading to a series of metabolites (see Fig. 1 ). 20 After being taken up by the neuron, noradrenaline is inactivated for storage or oxidatively deaminated by MAO to 3,4-dihydroxyphenylglycol before reduction and O-methylation by COMT to 3-methoxy-4-hydroxyphenylglycol. 21 Extraneuronal degradation of noradrenaline and adrenaline by the enzyme COMT leads to the formation of normetadrenaline and metadrenaline, respectively. Subsequent deamination and oxidation by MAO ¢nally leads to the formation of HMMA, the principal end-product of metabolism of both noradrenaline and adrenaline. 22, 23 The metabolism of dopamine closely resembles that of noradrenaline and adrenaline, with extraneuronal metabolism by COMT and MAO leading to the formation of 3-methoxytyramine, 3,4-dihydroxyphenylacetic acid and ¢nally HVA, the predominant end-product of dopamine metabolism.
Since dietary catecholamines are extensively conjugated before reaching the systemic circulation, free (unconjugated) catecholamine levels in plasma and urine are independent of dietary in£uences and more accurately re£ect endogenous production. In plasma, almost 99% of dopamine and some 60 -70% of circulating noradrenaline and adrenaline exist as conjugates with sulphate and are excreted along with their O-methylated derivatives in urine as glucuronide and sulphate conjugates. In contrast, the predominant catecholamine in urine is unconjugated dopamine, a substantial proportion of which is derived by de novo renal tubular synthesis from the catecholamine precursor DOPA. 24 Unlike the catecholamines and metadrenalines, HMMA and HVA are not signi¢cantly conjugated.
Analytical methodology
The analysis of catecholamines and their metabolites in tissue and biological £uids has generated an extensive literature that encompasses £uorimetric, spectrophotometric, radioenzymatic, GC, liquid chromatographic and immunoassay techniques. The relative merits of the various procedures have been reviewed, 25, 26 but, with the exception of HPLC, few applications have found widespread acceptance in clinical biochemistry laboratories. Weinkove 27 demonstrated that HPLC with electrochemical detection could provide a speci¢c and sensitive technique capable of automation and this is currently the preferred approach for the measurement of catecholamines and metabolites. However, immunoassays that have recently been developed show promise as a viable alternative to HPLC for the measurement of urinary catecholamines and metabolites. 28 Furthermore, the compact bench-top tandem mass spectrometers that can readily be interfaced to HPLC systems o¡er advantages in analytical sensitivity and speci¢city since detection is based on molecular mass and chemical structure, properties unique to each molecule.
Although HPLC combined with £uorescence or electrochemical detection can provide the necessary sensitivity for the analysis of catecholamines and metabolites, the initial puri¢cation step prior to chromatographic separation is of critical importance and cannot be overemphasized. Sample pre-treatment is often simpler with HPLC and electrochemical detection than with £uorescence detection as the latter frequently requires the formation of suitable £uorescent derivatives. However, electrochemical detectors are more susceptible to £uctuations in HPLC pumping rates, resulting in an increased signal-tonoise ratio; moreover, the mobile phase must be electrically conductive, restricting the choice of its composition.
Analysis of urinary HMMA and HVA
Historical aspects
HMMA, or VMA (vanillylmandelic acid) as it is often called in the literature, was the most frequently measured chemical marker for the assessment of excessive catecholamine production. Armstrong et al. 11 introduced a solvent extraction procedure, and Sandler and Ruthven 29 used ion-exchange isolation of HMMA followed by oxidation to vanillin with sodium periodate before Pisano et al. 14 pioneered a modi¢ed spectrophotometric procedure that was widely adopted. Although extensively used for HMMA estimation, the Pisano procedure was subsequently shown to lack analytical speci¢city. 30^32
Chromatographic methods
Adapting the Pisano spectrophotometric principle to HPLC 33 demonstrated the potential of a chromatographic approach to signi¢cantly reduce the problems associated with HMMA analysis. This was quickly followed in the late 1970s and mid-1980s by a plethora of GC 34, 35 and HPLC methods 36^38 which allowed the combined measurement of HMMA and other metabolites of interest such as HVA and 5-hydroxyindoleacetic acid. Combining GC procedures with mass spectrometric detection (GC-MS) has been successfully applied to the analysis of HVA levels in population screening programme s for neuroblastoma in many countries. 39, 40 
High-performance liquid chromatography
With the widespread availability of HPLC equipment, procedures for HMMA and HVA estimation focused on simplifying and improving the preliminary isolation techniques to limit the co-extraction of interfering compounds. Numerous procedures involving solvent extraction, 41 ion-moderated partition chromatography with anion exchange resins 42 and the use of small disposable, bonded-phase silica columns 43, 44 have been described. Many of the published methods can simultaneously isolate HMMA and HVA from urine with little alteration in the extraction conditions. 41^46 However, with the advent of more analytically speci¢c procedures for the estimation of urinary catecholamines, the diagnostic sensitivity of HMMA in the detection of phaeochromocytoma has been questioned. 47, 48 Currently, the measurement of HMMA is considered clinically more useful when used in conjunction with HVA analysis in the biochemical investigation and monitoring of neuroblastoma 40, 49 rather than the investigation of phaeochromocytoma.
Analysis of urinary free catecholamines
High-performance liquid chromatography HPLC methods greatly simpli¢ed the estimation of urinary catecholamines and enabled assays that were previously con¢ned to research laboratories to become routine procedures in clinical biochemistry laboratories. With the potential for automation, an HPLC approach allows the handling of a larger number of samples and the routine investigation of symptomatic, hypertensive patients. Many di¡erent HPLC methods for analysis have been described for the quanti¢cation of urinary free catecholamines, an indication that none are ideal even with the enhanced analytical speci¢city o¡ered by electrochemical or £uorimetric detection systems. Preliminary isolation and puri¢cation of the catecholamines from urine generally involves solid phase extraction based on the interaction of the cis-diol function of the catechol nucleus with either alumina, ion-exchange resins, boric acid and its derivatives or combinations of these procedures. 50^53 The choice of the pre-chromatographic isolation procedure will invariably be determined by the detection system employed. With £uorimetric detection, consideration must be given to interferences from drugs that possess £uorescent properties, such as a-methyldopa 54 or isoproterenol, while labetalol has been shown to interfere in HPLC procedures using electrochemical detection. 55 
HPLC with alumina isolation
Historically, the procedures pioneered by Weil-Malherbe and Bone 56 and von Euler and Lishajko 57 over 50 years ago, together with those described by Anton and Sayre 58 involving extraction onto acidwashed alumina at alkaline pH (8.6), have formed the basis of many HPLC procedures (see Table 1 ). A systematic appraisal of the alumina procedure by Bouloux et al. 59 found that commercial sources of acidwashed alumina (Alumina WA4, Sigma Chemicals, Poole, UK) could readily replace`in-house' preparations, while the choice of acid used to elute the adsorbed catecholamines can in£uence the resulting chromatography. In general, acids such as phosphoric acid, perchloric acid and acetic acid are suitable and have been extensively used, but hydrochloric acid as a desorbent requires an ethyl acetate wash to reduce chromatographic artefacts. 60 Many procedures have used alumina isolation in conjunction with HPLC and electrochemical detection for the analysis of plasma catecholamines, 61,62 but, as alumina will isolate all compounds with a catechol nucleus, the speci¢city of alumina isolation from urine samples is somewhat limited. 63 Alumina isolation alone as a sample preparation procedure for urine analysis is probably more suited to HPLC with £uorescence detection 64^66 than electrochemical detection irrespective of its use in a column or batch extraction mode. However, combining alumina isolation with a second isolation procedure such as silica-based disposable minicolumns can help resolve many of the problems inherent with initial alumina isolation but at the disadvantage of both cost and preparation time.
HPLC with ion-exchange isolation
As an alternative to alumina isolation, both weak and strong cation-exchange resins have been used for the isolation of free catecholamines from urine. 51, 67, 68 Strong cation-exchangers such as Dowex resins have the disadvantage of being less selective, while the selectivity of weak carboxylic acid ion-exchangers such as BioRex 70 can be improved by using elution with boric acid (see Table 1 ). 69^72 In this way, initial isolation occurs via the amine function, while elution with boric acid forms a complex with the cis-diol function of the catecholamines. Combining ionexchange isolation with alumina has also been reported to provide less interference on subsequent HPLC chromatograms but at the expense of increasing the sample preparation time. 52, 72 Commercial options are available for the isolation of urinary catecholamines (see Table 1 ); these are based on silica minicolumns with both strong and weak cation-exchange properties 73 but have the disadvantage of increased costs.
HPLC with boric acid isolation
The improved speci¢city achievable with boric acid isolation has been further extended to include the use of immobilize d phenylboronic acid gels and solidphase boric acid. 74^77 These gels di¡er mainly in the spacing of the boric acid from the support matrix and are believed to retain the catecholamines by forming a complex with the vicinal hydroxyl groups at increased pH. 77, 78 Elution is readily achieved by decreasing the pH, providing a simple and rapid procedure prior to HPLC analysis. However, one disadvantage previously noted was the variation in the properties of di¡erent batches of the gels. 79 This problem was avoided in an elegant procedure devised by Smedes et al. 80 involving complex formation with diphenylborate, ion-pair organic solvent extraction of the complex into a mixture of heptane and octanol before back-extraction of the catecholamines into acetic acid. This procedure produced recoveries of up to 100% for all three catecholamines and was further re¢ned by MacDonald and Lake who introduced an initial isolation step using a strong cation-exchange column. 81
Automated procedures
By immobilizing boronic acid derivatives on microparticulate silica, 82 many of the disadvantages of the boronic gels were avoided, permitting on-line HPLC pre-concentration and isolation of urinary catecholamines. 83 The urine sample can be injected directly into the HPLC system without prior puri¢cation and, by redirecting the HPLC mobile phase, the catecholamines are eluted from the initial pre-column for subsequent determination using reverse-phase HPLC.
Other on-line isolation techniques utilizing alumina or cation-exchange silica with column switching followed, 84, 85 demonstrating the potential of automation for the analysis of urinary catecholamines. This has been realized with fully automated commercial procedures that allow the rapid and simple measurement of urinary free catecholamine levels (see Table 1 ). The Gilson ASTED (automated sequential trace enrichment with dialysis) system 86 uses an in-line trace enrichment cartridge packed with ion-exchange silica, while the Gilson ASPEC (automated solid phase extraction for chromatography) analyser utilizes disposable pre-packed cartridges. Other commercial systems have been reported (see Table 1 ) and all have signi¢cant practical advantages compared with manual procedures for the handling of larger sample numbers from the increasing number of symptomatic hypertensive patients investigated for the possible presence of a catecholamine-secreting tumour. 27
Analysis of urinary normetadrenaline and metadrenaline
The catecholamine metabolites^normetadrenaline and metadrenaline^are excreted in urine as both free amines and as sulphate and glucuronide conjugates, with the free (unconjugated) levels representing 53% of the total urinary metadrenaline excretion.
Urinary normetadrenaline and metadrenaline are mainly derived by metabolism of circulating catecholamines by extraneuronal pathways 139 and as such are not signi¢cantly in£uenced by diet. 87 Historically, the spectrophotometric method described by Pisano was extensively used to measure total metadrenalines, i.e. the combined concentration of both normetadrenaline and metadrenaline in urine samples. 15 Subsequently, Shoup and Kissenger demonstrated the practical advantages that could be gained from the use of HPLC methods, allowing the separate measurement of normetadrenaline and metadrenaline levels in urine. 88 In addition, recent reports have reported the diagnostic superiority that can be obtained by the measurement of plasma normetadrenaline and metadrenaline using highly sensitive and speci¢c HPLC procedures. 89 Although a few studies have measured the unconjugated fractions in urine, 90^92 the preferred approach is to liberate the sulphate-conjugated metabolites. Consequently, urinary total metadrenalines (free amines plus conjugates) have generally been measured following a preliminary hydrolysis step. Traditionally, acid hydrolysis as described by Smith and Weil-Malherbe 93 and Pisano 15 and the subsequent adaptation of this procedure to HPLC 88 has been the preferred approach. Even though acid hydrolysis invariably results in highly pigmented urine samples for subsequent analysis, enzymatic hydrolysis has rarely been applied to metadrenaline analysis, being retained for the hydrolysis of more labile urinary metabolites. 94 HPLC is the most commonly used technique for measuring total metadrenalines (NEQAS data) and allows the measurement of individual normetadrenaline and metadrenaline concentrations. The original spectrophotometric procedure reported by Pisano 15 may still be in use, and laboratories using this procedure for initial screening of urine samples should be aware of the many limitations associated with this procedure. 95, 96 Chromatographic methods HPLC-based techniques for the measurement of metadrenalines o¡er a more practical approach than GC or £uorimetric procedures, as uniform HPLC conditions can be utilized for both urinary catecholamines and metadrenalines. 68, 70 Extraction of the metadrenalines from acid-hydrolysed urine has generally been achieved using weak cation-exchange resins of the sulphonic or carboxylic functional types as advocated by Pisano. 15 However, the complexity of the subsequent HPLC chromatograms using this approach has lead to many attempts to improve the isolation selectivity by employing a wide variety of ionexchange processes or combining ion-exchange isolation with solvent extraction. 97^99 Unfortunately, such HPLC methods are invariably complex and timeconsuming, requiring multiple solvent extraction and evaporation stages (see Table 2 ) or HPLC gradient elution to resolve the many extraneous peaks on the chromatograms. Other investigators have attempted to overcome the problems of limited isolation speci¢city by combining HPLC with more speci¢c detection systems such as tandem mass spectrometry (LC -MS/ MS), 100^102 £uorescence detection 103, 104 or an array of multiple coulometric detectors. 105 In contrast, Stewart et al. successfully adapted the ASTED automated system to measure both catecholamines and metadrenalines simultaneously in hydrolysed urine samples. 106 However, a simple procedure based on dual column chromatography with cation-and anion-exchange resins has been devised. 69, 70 Acid-hydrolysed urine samples are diluted with borate bu¡er to bind catecholamines before application to a cation-exchange resin. The eluate from this resin is subsequently applied directly onto a strong anion-exchange resin, e¡ectively separating the metadrenalines from nonphenolic amines and more hydrophobic compounds (see Table 2 ). The resulting chromatograms do not exhibit the complexity associated with other procedures. This procedure has recently validated by comparing results with those obtained by a GC-MS method. 107 With the exception of the automated ASTED procedure, 106 the measurement of normetadrenaline and metadrenaline levels will invariably require an initial puri¢cation step prior to any HPLCbased technique. Even highly sensitive and speci¢c analytical procedures such as LC-MS/MS 108, 109 require an extensive sample preparation technique. Furthermore, established HPLC procedures may be prone to interferences, 99, 110, 111 a criticism frequently levelled at the original spectrophotometric procedure of Pisano. 16
Analysis of plasma catecholamines
There is an expansive literature dealing with plasma catecholamine measurements based on analytical principles such as radioenzymatic, £uorescence or HPLC. Earlier workers such as Peuler and Johnson 112 pioneered the application of radioenzymatic analysis using single and double isotope methods to produce very sensitive assays requiring a small sample volume, typically 50 -100 mL. However, the methods are somewhat complex and tedious, requiring minute attention to detail, and are not suited to routine clinical chemistry departments. Even though catecholamines possess natural £uorescence, many other compounds and drugs present in plasma have absorption and emission maxima at the same wavelengths 113 and consequently £uorimetric methods require highly speci¢c isolation techniques. While conversion of the catecholamines to £uorescent derivatives with trihydroxyindole or ethylenediamine can enhance sensitivity, speci¢city is still limited due to drugs and dietary interferences. 7^9 Combining HPLC with £uorescence detection and using precolumn 114 or post-column derivatization 115 can resolve some of the disadvantages, but HPLC with amperometric or coulometric detection (HPLC-EC) is the dominating analytical procedure for plasma catecholamine analysis. The main advantage of HPLCbased procedures is versatility since, with minimum changes to chromatographic conditions, urinary catecholamines and metabolites can also be measured.
Pre-treatment of plasma samples for catecholamine analysis has generally involved extraction onto acidwashed alumina at basic pH acid, 58^62,69 or the use of boric acid isolation. 75^81 The major analytical challenge lies in achieving the required sensitivity for the low levels of plasma catecholamines encountered while restricting the co-elution of the many endogenous and exogenous compounds that remain following such a non-selective process as alumina isolation. 59, 81 Some investigators have combined alumina isolation with cation-exchange resins in an attempt to overcome the limited speci¢city, but at the expense of lower recoveries, 67, 116, 117 whilst others have described the advantages of using`on-line'sample pretreatment or microbore HPLC columns (inner diameters of 51 mm) to improve assay sensitivity. 83, 118 Even though it is not a selective process, many procedures still involve the use of acid-washed alumina and, with careful attention to standardization, this approach can provide reliable analysis. Particular attention should be given to the HPLC conditions as the selection of mobile phase and electrochemical oxidation potential has been shown by Bartlett 119 and Krstulovic 120 to in£uence selectivity signi¢cantly. Simple alterations in the concentration of organic modi¢er or ion-pairing counter-ion can yield signi¢cant changes in chromatographic separation and provide the opportunity to resolve problems encountered with the co-extraction of interfering compounds. Nevertheless, such modi¢cations can subsequently alter the chromatographic behaviour of other interfering substances, with unpredictable consequences.
In an excellent review of plasma catecholamine analysis, Hjemdahl advocates the use of cationexchange HPLC columns in preference to the more popular reverse-phase with ion-pairing agent as this o¡ered a more dependable separation with fewer problems encountered from interfering peaks. 121 An HPLC cation-exchange technique is available containing all necessary reagents, although other manufacturers have chosen to standardize the conditions for isolation and provide customized reversephase HPLC separation (see Table 1 ). In contrast to techniques involving manual extraction, Dutton et al. showed that the Gilson ASTED automated system could be readily adapted for plasma catecholamine analysis, providing good analytical precision and eliminating the manual extraction steps. 122 Irrespective of the isolation technique selected, clearly the analysis of plasma catecholamines by HPLC-EC requires a greater degree of attention than urinary catecholamine analysis, and newly developed assays should be validated against those of a well-established procedure. By changing the HPLC conditions, it is possible to compare results obtained for each sample, using the same alumina extraction technique but employing alternative HPLC conditions of analysis such as cation-exchange or reverse-phase ion-pairing conditions. This can help identify problems associated with analytical speci¢city and selectivity. In this context, Rosano and Whitley 69 report details of a plasma catecholamine assay using alumina isolation with an ion-exchange-based HPLC method, while Eisenhofer 123 provides extensive details of an alumina-based extraction procedure coupled with reverse-phase HPLC.
Analysis of plasma normetadrenaline and metadrenaline
Recent reports have highlighted the enhanced clinical bene¢ts that the measurement of fractionated plasma metadrenalines o¡er in the investigation of chroma¤n cell tumours, 89, 124, 125, 132, 133 a normal result for plasma metadrenalines making the presence of a phaeochromocytoma highly unlikely. Whilst there is an extensive literature dealing with plasma catecholamine analysis, measurement of plasma metadrenalines has involved either radioenzymatic or HPLC-based procedures. Metadrenalines are normally present in plasma at concentrations lower than those of the catecholamines (see Tables 3 and 4 ) and thus require highly sensitive and speci¢c procedures. In early studies, Kobayashi et al. 126 and Foti et al. 127 achieved the necessary sensitivity by using a radioenzymatic approach to measure solely plasma normetadrenaline levels. Later studies involving HPLC with £uorimetric detection 51, 128 showed promise but proved to have inadequate sensitivity and speci¢city, yielding plasma concentrations that were substantially higher than those obtained with a radioenzymatic approach. 132 Further re¢nements to HPLC-based procedures were reported by Pagliari et al. 129 and Mornex et al., 130 who introduced the use of strong and weak ion-exchange resins for the preliminary isolation of the metadrenalines from plasma prior to measurement by HPLC with electrochemical detection. Because of the low concentrations of the unconjugated metadrenalines in plasma, total (free+ unconjugated) normetadrenaline and metadrenaline were measured. 129, 130 A more analytically sensitive HPLC-EC method was later devised by Lenders et al. 131 employing silica-based disposable cation-exchange columns, and this has formed the basis of most of the existing procedures currently in use. 124 ,132^134 Without doubt, the analysis of plasma metadrenalines requires any HPLC-based procedure to achieve the highest levels of analytical sensitivity for reliable results. 135 However, with the development of reliable immunoassays for urinary total metadrenalines, such procedures may o¡er a viable alternative in the future. 28, 136 At present, however, the question concerns not the choice of method but whether the measurement of plasma unconjugated or plasma total metanephrines represents the optimum biochemical approach for the diagnosis of phaeochromocytoma. 87, 137, 138 Plasma total metadrenalines have been determined after acid hydrolysis or enzymatic deconjugation with sulphatase to release sulphate-conjugated metabolites. 89, 129, 130, 133 This produces plasma total concentrations some 20 -30-fold higher than free concentrations, thus making their estimation less technically demanding. However, the circulatory clearance of sulphateconjugated metadrenalines as end-products of catecholamine metabolism is dependent almost entirely on elimination by the kidneys. Thus plasma concentrations of total metadrenalines can be grossly elevated in patients with impaired renal function, limiting their diagnostic speci¢city. 129, 130 Lenders et al. 89 compared total and unconjugated metadrenalines in the diagnosis of phaeochromocytoma and concluded that total concentrations o¡ered no advantages over unconjugated concentrations. The presence of a tumour produced larger increases in free normetadrenaline concentrations than in total normetadrenaline concentrations. However, Grouzmann et al. 133 argue that the longer half-life of sulphateconjugated metadrenalines should minimize wide variations in plasma concentrations that might arise from intermittent release by a tumour.What is clear is that plasma metadrenalines have superior diagnostic sensitivity than plasma catecholamines for the diagnosis of phaeochromocytoma and as such provide a more reliable marker for the presence of a phaeochromocytoma. 139 Immunoassay Several immunoassay procedures have been proposed in the past for the measurement of catecholamines and metabolites, 140^142 but problems associated with antibody speci¢city for such low molecular size haptens have restricted their widespread acceptance. Commercial assays have been developed for urinary HMMA 143 but, even with monoclonal antibodies, poor correlation with HPLC-based procedures was observed due to cross-reaction with compounds similar in structure that were present in urine. 144 As catecholamines and metadrenalines do not possess su¤cient immunogeneic properties, immunoassays depend on raising antibodies against N-acylated derivatives formed by reaction with Bolton-Hunters reagent. 140^142 Various investigators have described methods for producing antibodies to the metadrenalines and have incorporated the antibodies in 51 100-780** 60-380** 87 32 180-650* 100-630** 131 32 120-730** 60-200** 131 178 100-610*** 60-310*** 125, 135
Total levels 18 100-10 000* 50-500* 133 33 50-38 000** 100-1700*** 133 178 3330-17 320*** 160-8660*** 135 *Normotensive subjects; **hypertensive subjects; ***normotensive and hypertensive subjects. HPLC-EC, high-performance liquid chromatography with electrochemical detection.
COMT-catalysed reaction techniques. 145, 146 In this context, the catecholamines are isolated using boric acid or alumina extraction followed by enzyme-catalysed methylation with COMT, converting noradrenaline and adrenaline into their relevant metadrenalines before reaction with the relevant antiserum raised against N-acylated metadrenalines. Unlike the catecholamines, metadrenalines do not require an isolation step for subsequent immunoassay. While older procedures relied on an additional chromatographic separation to enhance sensitivity and speci¢city, newer, simpler non-isotopic or radioimmunoassay test kits with all necessary reagents are now commercially available (see Table 1 ). The usefulness of such procedures was recently studied by Wassell et al., who reported a comparison of immunoassay results for urinary catecholamines and acidhydrolysed metadrenalines with HPLC values and showed lack of interferences from a wide range of medications. 28 Using a similar commercial kit, Wolthers et al. 136 compared results for urinary metanephrines obtained by an enzyme immunoassay-based procedure with a GC-MS method and concluded that such kits could reasonably be applied in the biochemical detection of phaeochromocytoma. However, Kerbi et al., investigating the feasibility of a neuroblastoma screening programme for children in late infancy based on an immunoassay for HVA, concluded that a back-up procedure using HPLC was essential in order to avoid false positive results. 147 With an immunoassay approach, it must be remembered that each individual catecholamine or metabolite requires a separate kit for analysis, unlike HPLC-based procedures in which several analytes can be quanti¢ed simultaneously within one analysis run. Nevertheless, such kits may provide a viable alternative to HPLC. 28
Pre-analytical considerations
Type of urine specimen
With neonates and small children, random urine specimens have replaced 24-h collections because of the practical di¤culties associated with timed urine collections in small children. 49, 148 Whilst random urine samples have also been proposed for diagnosing phaeochromocytoma in adults, 149, 150 the measurement of free catecholamines and total metadrenalines has generally been undertaken using 24-h urine samples since this represents an integrated index of catecholamine excretion over the extended collection period. However, the problems associated with completeness of 24-h urine collections has led to proposals for alternative collection strategies involving fractional timed urine collections or volume correction by expressing results as ratios to creati-nine. 112, 151, 152 This may, however, lead to further complications since creatinine output exhibits a high degree of biological variability. 153 Alternatively, with phaeochromocytomas that secrete catecholamines only paroxysmally, collecting random urine samples following`paroxysmal episodes' can provide useful clinical information. A simple and convenient approach for the investigation of individuals with a high degree of clinical suspicion of a catecholamine-secreting tumour was proposed by Ganguly et al. 154 and involved measuring noradrenaline concentrations in overnight urine specimens. Since catecholamines exhibit diurnal variation in excretion, 155 the elimination of environmental and emotional stimuli in association with recumbency results in a nocturnal decline in catecholamine excretion in normal subjects. This was shown by Dabrowska et al. 156 to be clinically useful in patients with a catecholamine secreting tumour, whilst MacDougall et al. also highlighted the bene¢ts of overnight urine collections when used in conjunction with clonidine suppression testing in the diagnosis and exclusion of phaeochromocytoma. 157 The e¤cacy of overnight urine collections for the detection of phaeochromocytoma was further demonstrated by Peaston et al., 158 who measured the overnight excretion rates for catecholamines and metabolites in a group of 16 patients with histologically proven phaeochromocytoma, 166 patients with hypertension and 24 normotensive subjects. Autonomous secretion of catecholamines and metadrenalines was evident in all patients with phaeochromocytoma and provided a better diagnostic sensitivity and speci-¢city than 24-h urine collections. It was noted that use of overnight urine samples simpli¢ed the collection protocol for patients while avoiding the e¡ects of stress and exercise on catecholamine excretion. The investigation of patients with a suspected catecholamine-secreting tumour generally requires more than one urine collection to avoid the possibility of missing episodic secretors. As such, overnight urine collections can be readily incorporated into existing strategies for the investigation of patients and o¡er a viable alternative to 24-h specimens. Abnormal results from overnight urine samples can be readily followed up by collection of 24-h urine samples if required for veri¢cation.
Sample stability and storage Urinary catecholamines and metabolites
Recent studies investigating the stability of catecholamines and their metabolites in urine collections have demonstrated the need to reduce the pH of the urine collection to less than 3.5. 27, 86 ,159^161 Even at pH 3.0, some loss of catecholamines has been demonstrated. 161 The choice of acid (hydrochloric, acetic or sulphuric acid) to use as a stabilizing agent is less important than ensuring that the urine pH is reduced as soon as possible to prevent degradation. Although hydrochloric acid has been extensively used as a stabilizer, sulphuric acid has been recommended as the preservative of choice when using the ASTED sample preparation system. 27, 86 In direct contrast to the need for an acid stabilizer, Moleman 162 proposed that 0.5 g of EDTA and sodium metabisulphite in the collection vessel was su¤cient to stabiliz e 24-h urine samples for catecholamines and metadrenalines for up to 2 weeks at 7208C and at 7808C for longer storage. However, our experience with this approach has shown that the storage temperature of the urine during the sample collection period can have a profound in£uence on catecholamine stability. Other reports have also suggested that catecholamines may be stable in unpreserved random urine samples, but specimens required immediate storage at 7208C. 163 Many of the urine samples for estimation of catecholamines and metabolites are collected from patients attending outpatient clinics who are given speci¢c instructions for the collection and subsequent storage of 24-h urine specimens. Controlling the wide variation in storage conditions is virtually impossible and adding a ¢xed volume of acid to the collection container before commencing the urine collection is recommended to avoid loss of catecholamines. In addition, the inclusion of 10-20 g of sand (BDH product no. 330947G) in the collection vessel to form a slurry with the acid preservative provides a simple means of minimiz ing spillage of the acid without compromising subsequent HPLC -EC analysis for catecholamines and metabolites. Providing the pH of the urine sample is below 3.5, urinary catecholamines are stable for up to 5 days at room temperature 203 and for many months at 7208C, and can be readily transported to referral centres for analysis. Experience has also shown that urinary metadrenaline levels are considerably more stable in urine collections than the parent catecholamines and were recently reported to be stable at room temperature for up to 7 days in urine samples collected without any acid preservative. 107, 109, 164, 203 Thus urine collections that may be invalid for catecholamine estimation may still be viable for metadrenaline analysis.
Plasma catecholamines
The stability of catecholamines and their metabolites in plasma has attracted signi¢cantly more attention than the study of their stability in urine collections. Excellent reviews of the problems associated with sample handling and preparation for liquid chromatographic assays for plasma catecholamines have been reported by Goldstein, 165 Nyyssonen and Parvianen, 113 Hjemdahl 121 and Bouloux et al. 59 There are a number of variables that must be considered when collecting blood samples for plasma catecholamine determination. These include: the time of day, as noradrenaline exhibits a diurnal pattern; sampling site, as arterial catecholamine concentrations are lower than venous concentrations; environmental stress; in£uence of posture, as plasma catecholamines concentrations can increase 2-3-fold from a supine to an upright position; and the in£uence of smoking and ca¡eine intake on subsequent levels. 165 The collection of blood samples for catecholamine analysis has thus resulted in a profusion of protocols. These include the addition of antioxidants such as ascorbic acid, 166 EDTA, 167 EGTA with glutathione 114 or sodium metabisulphite 58 to heparinized blood prior to centrifugation and storage of plasma at 7208C or 7808C. Most published procedures for measuring plasma catecholamines recommend rigorous protocols for the separation of plasma as soon as possible after blood collection in order to minimize loss of catecholamines. Investigators have concluded that plasma catecholamines are stable without antioxidant in plasma for up to 6 weeks at 7208C, 59 and for at least 1 year at 7808C. 121, 165 As stated by Hjemdahl, 121 the storage temperature of samples is most important, and plasma should be stored at 7808C whenever possible. It may also be prudent to incorporate antioxidants such as ascorbic acid in the sample preparation protocol 166 as this was shown to stabilize eluates for as long as 24 h at room temperature. The collection, handling and preparation of plasma samples for catecholamine measurement must be carefully controlled and standardiz ed for valid, reproducible results. The use of an in-dwelling venous catheter, a recumbent resting position for the patient of at least 30 min before sampling, transportation of EDTA or heparinized blood samples to the laboratory on ice and centrifugation preferably at 48C within 30 min before storage at 7808C are the minimum precautions that are required for collection of samples for plasma catecholamine measurement.
Plasma metadrenalines
In contrast to plasma catecholamines, plasma metadrenalines are signi¢cantly less susceptible to shortterm increases from external in£uences such as changes in posture or stress, and blood samples can be taken from patients in either in a sitting or lying position. 131^135 This independence of plasma metadrenaline concentrations on external in£uences should remove the need for the carefully controlled blood sampling protocols necessary for plasma catecholamine samples. However, all reports to date have adopted the same sampling protocols for plasma metadrenalines as for plasma catecholamines since studies have compared their diagnostic sensitivity and speci¢city. 124 ,131^135 Blood samples were collected on ice and centrifuged within 30 min for subsequent storage at 7808C.
Analytical considerations Accuracy
At present, there are no recognized de¢nitive or reference procedures for the analysis of catecholamines or metabolites. Several GC-MS and HPLC-MS procedures have been reported for plasma and urine analysis 39,40,91,100^102,106,107,168 and, although not available in most laboratories, MS can provide an invaluable source for validating the accuracy of methods in routine use. Whilst HPLC o¡ers a more practical and versatile approach for the routine analysis of catecholamine and metabolites, HPLCbased procedures are not without limitations, and critical appraisal of any result for potential sources of inaccuracy should be undertaken.
Potential sources of inaccuracy
Although attempts have been made to characterize potential sources of interferences with plasma catecholamine analysis, 169^171 urine samples for the analysis of catecholamines and metabolites will invariable contain a wide range of antihypertensive drugs, making the analysis an almost impossible task to achieve with urine specimens. Among the many potential sources of inaccuracy in HPLC-based methods, drug interferences can signi¢cantly in£uence results by co-eluting with peaks of interest or by altering sample recovery during the specimen preparation stage. 172, 173 Particularly suspicious is the ¢nding of a raised adrenaline result in the absence of increased noradrenaline concentration. Even with sophisticated HPLC integration packages, careful and critical assessment of HPLC chromatograms is essential if interfering compounds and sources of inaccuracy are to be detected and avoided. Particular attention should be paid to internal standard recoveries, alterations in the relative peak retention times of compounds of interest or internal standards along with relative peak broadening and peak symmetry to help identify the presence of interfering compounds. All methods should be evaluated by including samples from patients undergoing treatment with a range of antihypertensive drugs and other compounds known to cause interference in catecholamine assay methods. 54, 55, 63, 172, 173 Comparing the procedure with another method based on di¡erent assay principles should help validate the analytical accuracy. Nevertheless, careful and critical evaluation of HPLC chromatograms is still recommended to identify possible sources of inaccuracy.
In the absence of an international reference preparation, assessment of accuracy will depend on the use of a calibration material of known purity, recovery experiments and participation in external quality control assurance programmes. Catecholamines and metabolite are readily available as the free base or as hydrochloride or bitartrate salts and exhibit stability in dilute hydrochloric, perchloric or sulphuric acids. Several quality assurance programmes are currently available for quality assessment of urinary catecholamines, metadrenalines, HVA and HMMA concentrations. In addition to supplying suitable material for internal quality control, commercial suppliers (see Tables 1 and 2 ) also o¡er a`turn-key' approach to analysis by providing all the necessary reagents, standards, extraction kits and hardware such as HPLC columns to ensure a standardiz ed and reproducible approach if the instructions are followed closely.
Factors in uencing catecholamine excretion
Although physiological and pathophysiological factors such as physical activity, emotional stress, food intake and hypoglycaemia can have a signi¢cant e¡ect on circulating catecholamine concentrations, 23 such short-term changes rarely impact on 24-h urinary catecholamine or metabolite concentrations. However, catecholamine excretion does exhibit a diurnal variation 154^158 and plasma concentrations can be signi¢cantly in£uenced by posture, with increased levels in ambulant subjects. The renal handling of catecholamines is complex and, in patients with renal insu¤ciency or renal failure, plasma catecholamines or metadrenalines can be increased 2-or 3-fold above the upper reference limits in non-phaeochromocytoma patients. 174 Drugs can also have a signi¢cant in£uence on catecholamine concentrations in both urine and plasma. Not only can medications such as labetalol or amethyldopa interfere with many methods, 171^173 but drugs can induce increased or decreased levels of catecholamines and metabolites through their pharmacological mode of action. 69 This in£uence of medications on catecholamine concentrations must be considered when establishing reference data for catecholamines and metabolites and values should be derived from as diverse group of subjects as possible. Examples of published reference ranges for urinary catecholamines and metadrenalines in adults are shown in Tables 5 and 6 , respectively. Although no signi¢cant di¡erences in excretion have been observed between sexes, it has been shown that normetadrenaline excretion but not metadrenaline increases with age, 175, 176 similar to the pattern observed with plasma catecholamine concentrations. 177 Experience in dealing with phaeochromocytoma in children has been reported, 178 whilst some studies have provided age-related reference intervals in random urine samples from children. 179^182 In a detailed review of the literature, Fitzgibbon and Tormey included paediatric reference ranges for children, along with a discussion of their relevance in the diagnosis of neuroblastoma. 183
Laboratory detection of catecholamine-secreting tumours
Catecholamine-secreting tumours such as neuroblastomas, phaeochromocytomas or paragangliomas are rare tumours that arise in chroma¤n tissue. Their anatomical distribution closely parallels the sites where chroma¤n cells are present at the time of birth, such as the sympathetic nervous system, autonomic ganglia, adrenal medulla and paraganglia cells. Fundamental to the diagnosis of such tumours is the biochemical measurement of catecholamines or metabolites in plasma or urine. There is still, however, a diversity in opinion on the most e¡ective biochemical strategy for the detection of these tumours. 47, 48, 106 
Neuroblastomas
Neuroblastomas originate from ectodermal neuroblasts in the adrenal medulla or other sites anywhere in the body in which sympathetic tissue is present. It is one of the most common malignant tumours of childhood, usually presenting before the age of 3 years; the tumour is most commonly in the abdomen (60%) with some 70% of these adrenal-based. Neuroblastomas commonly present as an asymptomatic mass, exhibiting rapid growth and widespread metastasis to adjacent lymph nodes. Approximately 90 -95% of neuroblastomas are associated with excessive production of catecholamines and metabolites, with symptoms of sweating, £ushing, headaches, diarrhoea and acute cerebellar encephalopathy. The tumour can regress spontaneously in young infants but rarely in older children and can be classi¢ed into four stages (see Box 1) . Clinically the most acceptable approach for the detection of these tumours involves the measurement of HVA, HMMA and dopamine concentrations in random urine samples which, together with age and staging, can help determine prognosis and guide treatment.
Phaeochromocytoma
The incidence of phaeochromocytoma has been estimated to be in 50.5% of hypertensive patients. Diagnosis is important because the hypertension is usually curable by surgical extirpation and, as there is a high incidence of cardiovascular complications associated with the condition, it is imperative that diagnosis is not missed or delayed. 184^186 Among the diverse clinical features, hypertension is the most common presentation, with symptoms of headaches, excessive sweating and palpitations present in more than 90% of patients. 186 However, a few patients may be normotensive or in rare cases hypotensive due to the secretion of predominantly adrenaline or dopamine. 187 A signi¢cant number of phaeochromocytomas are discovered at autopsy, emphasiz ing that many patients may be quite asymptomatic during their lifetime. 188^190 Phaeochromocytomas can be classi¢ed as sporadic or familial, with most being sporadic.
In adults, 90% of phaeochromocytomas occur in the adrenal medulla, with approximately 10% bilateral. Extra-adrenal phaeochromocytomas (paragangliomas) occur in chroma¤n cells within the sympathetic paraganglionic axis and, whilst they have a tendency to secrete excess noradrenaline, many of these tumours can be non-functional with no biochemical evidence of catecholamine excess in plasma or urine. 191, 192 Hereditary forms of phaeochromocytoma have been described in association with multiple endocrine neoplasia (MEN) type 2, von Hippel-Lindau disease and von Recklinghausen's neuro¢bromatosis. Phaeochromocytoma in MEN 2 is associated with germline mutation of the proto-oncogene RET, and screening families for such mutations has improved the clinical management of patients with hereditary phaeochromocytoma. 184 Diagnosis of phaeochromocytoma depends on a high index of clinical suspicion (see Box 2) and biochemical con¢rmation of excessive catecholamine secretion. Recently, measurement of plasma metadrenalines has been recommended as the ideal procedure for the detection and exclusion of the presence of phaeochromocytoma in both adults and children. 193, 194 Free metadrenalines measured in plasma by HPLC -EC were observed to provide diagnostic sensitivities and speci¢cities as high as 100% and 89%, respectively, for detecting phaeochromocytoma. 87, 130 At present, however, measurement of plasma metadrenalines is not widely available and the estimation of catecholamines and metabolites such as metadrenalines in urine collections is the mainstay of initial biochemical investigations. Plasma catecholamine measurements have limited diagnostic usefulness.Whilst plasma samples may be more convenient, the di¤culties associated with the collection of such samples and the limitations of basal plasma catecholamines to detect phaeochromocytoma are widely recognized. 195^197 A single plasma measurement can miss a phaeochromocytoma with episodic secretion, whereas 24-h or overnight urine collections provide an integrated index of catecholamine secretion. However, plasma analysis may provide the only useful diagnostic test in the anuric/oliguric patient. More than 80% of patients with phaeochromocytomas will have urinary free catecholamine and metadrenaline concentrations greater than twice the upper limit of normal (seeTable 7). A reliable screening approach is the measurement of fractionated metadrenalines in more than one urine collection. Several studies have highlighted the bene¢ts of measuring urinary fractionated metadrenalines as the front-line test for discriminating secondary causes of hypertension and phaeochromocytoma. 47, 48, 183, 198, 200 When there are practical di¤culties with this approach, the measurement of urinary free catecholamines supplemented as frequently as possible with the measurement of urinary fractionated metadrenalines increases the likelihood of detecting a phaeochromocytoma. With unequivocally high urinary catecholamine concentrations, measurement of fractionated metadrenalines provides further biochemical con¢rmation. Combining catecholamine and metadrenaline measurements can be useful to distinguish borderline increases in catecholamine excretions from nontumour sources or when clinical suspicion indicates the possible presence of a phaeochromocytoma. Sawka et al. 204 compared the diagnostic e¤cacy of 24-h urinary total metadrenaline and free catecholamine concentrations with measurement of fractionated plasma metadrenalines in samples from 349 outpatients. Whilst the measurement of combined urinary metadrenalines and catecholamines provided a lower rate of false -positive testing, normal plasma metadrenaline levels were observed to e¡ectively rule out the diagnosis of phaeochromocytoma in asymptomatic patients. 204 It is important to recognize that there is no single, perfect urinary screening test for the biochemical detection of phaeochromocytoma.
Analysis of repeat urine samples should always be considered to exclude or con¢rm the possible presence of a phaeochromocytoma. If clinical suspicion is high and catecholamines and metadrenaline results are equivocal, further analysis of urine collections on two to three occasions should be undertaken, ideally at a time when the patient is symptomatic.
In the majority of patients it is not necessary to restrict diet or medication prior to urinary screening. Labetalol can interfere with many catecholamine and metadrenaline assays and should be discontinued 4-7 days before re-testing. In addition, some patients may require further investigations to exclude the possible diagnosis of phaeochromocytoma. Pharmacological suppression or stimulation testing in conjunction with plasma or urinary catecholamine measurement has been utilized 161, 199, 200 but requires careful monitoring by experienced clinicians, as both procedures may be hazardous.
For the anatomical localization of suspected tumours, CT scanning can visualize most phaeo-chromocytomas, while MRI has a higher speci¢city for paragangliomas. In addition, methyl[ 123 I]iodobenzylguanidine, a chroma¤n cell binding analogue, is especially useful for detecting benign, recurrent or metastatic phaeochromocytoma. Following biochemical and localization con¢rmation of a possible phaeochromocytoma, the mainstay of pre-operative management is a-adrenergic blockade with phenoxybenzamine, with the addition of b-blocking agents such as propranolol to reduce major side-e¡ects such as orthostatic hypertension. Most patients become normotensive after successful resection of phaeochromocytoma, but a few remain hypertensive. Follow-up consists of clinical and biochemical assessment several times during the ¢rst year and then yearly testing of urine samples. Malignant phaeochromocytomas, which may occur in about 10% of patients, can only be diagnosed at operation when the tumour is locally invasive and unresectable, or recurs after primary extirpation or is found to be metastatic.
Conclusion
There is a plethora of procedures available for the measurement of catecholamines and metabolites using the versatility of HPLC with £uorescence or electrochemical detection. The greater degree of analytical speci¢city achievable with HPLC-EC procedures has signi¢cantly reduced but not completely removed the impact of drug interferences, and a critical awareness of such limitations is required. Immunoassay techniques have been developed that remove the need for dedicated HPLC equipment and o¡er a viable alternative for the laboratory detection of phaeochromocytoma. The enhanced sensitivity and speci¢city of liquid chromatography-tandem mass spectrometry systems makes it likely that rapid screening of large numbers urine and plasma samples for metadrenaline concentrations may become more common, removing the need to employ specializ ed collection protocols. Whilst the diagnostic sensitivity and speci¢city of urinary catecholamines is su¤cient to detect the majority of catecholamine-secreting tumours, plasma or urinary metadrenalines have been shown to be highly reliable biochemical indices for the detection of phaeochromocytoma.With a wide variety of clinical presentations and secretory patterns, a planned approach to the biochemical detection of phaeochromocytoma using a combination of markers will provide the optimum strategy. Interpretation of biochemical results should be related in terms of the magnitude of the increase above reference intervals rather than simply an increased result. A patient with signi¢cantly elevated results and relevant clinical symptoms is far more likely to have a catecholamine-secreting tumour than a patient with the same symptom but a nominal, borderline increase in catecholamine or metadrenaline excretion. Repeat urine collections should always be considered in such patients before proceeding to suppression testing.
The recommended approach for the detection of phaeochromocytoma:
. Overnight timed urine collections. . Sample preserved in dilute acid. . Measurement of urinary normetadrenaline, metadrenaline and catecholamine excretion by HPLC with electrochemical detection. . Abnormal results are well above an age-matched, treated hypertensive population. . Reserve plasma measurements for: anephric patients; tumour location where conventional scanning fails; exclusion of autonomic nervous dysfunction.
